Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
OmniAb is a biotechnology platform company providing transgenic animal technologies and antibody discovery services to pharmaceutical and biotech partners. The company licenses its proprietary OmniAb platform (including OmniRat, OmniMouse, OmniChicken, and OmniFlic technologies) for therapeutic antibody development, generating revenue through upfront fees, milestones, and royalties on commercialized drugs. With negative operating cash flow of approximately $20M annually and a 100% gross margin on minimal revenue, OmniAb operates as a pre-commercial stage platform company dependent on partner success.
OmniAb monetizes proprietary transgenic animal platforms through multi-tier agreements: upfront licensing fees ($1-5M range typical), research service fees during discovery phase, development milestones tied to clinical progression (Phase 1/2/3, regulatory approval), and low single-digit royalties on commercial sales. The business model exhibits high operating leverage once platforms are developed, as incremental licensing requires minimal variable costs. Competitive advantages include established IP portfolio around humanized antibody generation, existing relationships with 15+ pharma/biotech partners, and technical differentiation in generating difficult antibody classes. However, the company faces long monetization cycles (8-12 years from discovery to royalty generation) and concentration risk with limited active programs.
New platform licensing deals with pharmaceutical partners (deal size, partner quality, therapeutic area)
Clinical trial progression of partner programs using OmniAb technology (Phase advancement triggers milestone payments)
Royalty-bearing product approvals or commercial launches by partners (validates platform, creates recurring revenue)
Platform technology expansions or acquisitions that broaden addressable antibody classes
Cash runway visibility and financing events (equity raises, strategic partnerships with upfront payments)
Technological obsolescence risk from competing antibody discovery platforms (phage display, single B-cell technologies, computational design) that could reduce demand for transgenic animal approaches
Long monetization cycles (8-12 years discovery-to-royalty) create extended periods of cash burn with uncertain payoff, requiring sustained access to capital markets
Regulatory changes affecting animal research or antibody therapeutic approval pathways could impact platform utility or partner development timelines
Competition from established antibody platform providers (Harbour BioMed, Ablexis, Adimab) and in-house capabilities at large pharmaceutical companies reduces pricing power and market share
Partner concentration risk: limited number of active licensing agreements means loss of key partnerships materially impacts revenue trajectory
Commoditization risk as antibody discovery technologies mature, potentially compressing licensing fees and milestone structures
Negative operating cash flow of ~$20M annually with $200M market cap creates equity dilution risk through future financing rounds
Revenue decline of -22.8% YoY indicates potential partnership attrition or milestone payment lumpiness, increasing cash runway uncertainty
While 5.0x current ratio appears strong, absolute cash balance must support 2-3+ years of operations to reach meaningful milestone inflection points
moderate - Pharmaceutical R&D spending exhibits relative stability through economic cycles as drug development timelines span 10+ years, but biotech financing conditions tighten during recessions. OmniAb's partner base (large pharma vs venture-backed biotech mix) determines sensitivity: large pharma partnerships provide stability while smaller biotech clients face funding pressure during downturns. Platform licensing decisions are strategic rather than discretionary, providing some insulation from GDP fluctuations.
Rising interest rates negatively impact OmniAb through multiple channels: (1) higher discount rates compress valuation multiples for pre-revenue biotech stocks, (2) tighter venture capital funding reduces biotech client budgets for platform licensing, (3) increased financing costs for OmniAb's own operations given negative cash flow. The company's 5.0x current ratio provides liquidity buffer, but sustained high rates pressure the biotech ecosystem broadly. Conversely, falling rates improve financing conditions for both OmniAb and its customer base.
Moderate exposure through biotech customer credit risk. OmniAb's milestone and royalty-dependent model creates counterparty risk if partner companies fail to advance programs or face financial distress. Tightening credit conditions reduce biotech IPO/financing activity, shrinking the addressable customer base for platform licensing. However, minimal debt (0.08 D/E ratio) insulates OmniAb from direct credit market stress on its own balance sheet.
growth - Attracts speculative biotech investors focused on platform optionality and long-term royalty potential rather than near-term profitability. The -235% net margin and minimal revenue profile appeals to investors willing to underwrite 5+ year timelines for partner pipeline maturation. High volatility and binary outcomes (partnership wins/losses, clinical trial results) suit risk-tolerant growth portfolios. Value investors typically avoid given negative cash flow and uncertain path to profitability. The 0.7x price/book suggests some value characteristics, but reflects intangible platform assets rather than traditional value metrics.
high - Biotechnology platform stocks exhibit elevated volatility driven by binary partnership announcements, partner clinical trial results, and biotech sector sentiment swings. The -53.3% one-year return and small $200M market cap amplify price movements on low trading volumes. Stock reacts sharply to quarterly cash burn updates, financing announcements, and broader biotech index performance. Beta likely exceeds 1.5x relative to biotech sector indices.
